|
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets 20-Oct-2023 / 15:18 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Berlin, 20 October 2023. The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. A separate decision will be taken at a later date on the specific start and the manner of the exit. In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. PTX also includes Myelo Therapeutics GmbH.
Given the enormous growth forecast for active pharmaceutical ingredients, which is already reflected in the order intake, Eckert & Ziegler intends to pool its financial resources to expand its global manufacturing capacities. Eckert & Ziegler is thus concentrating on its core competencies in order to further expand its position as a leading supplier of radioisotopes for the production of radiopharmaceuticals. The forecast for the financial year 2023 remains unchanged. Contact: End of Inside Information 20-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
COVID’s Heart Damage; Watchdog Halts Psych Trials; Double-Check That Soft-Serve
Note that some links may require registration or subscription. Clinicians continue to struggle to understand and manage COVID-related heart damage. (AP) The suicide rate in
August 12, 2023